20/20 Biolabs, Inc. (AIDX) stock

AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/3062% below fair value

$0.20+0.00 (+0.25%)

Close on Nov 13, 2026Market cap $2.61MP/E –Yield –

20/20 Biolabs price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

20/20 Biolabs's price to sales ratio was 1.3× on Nov 11, 2026.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	1.3×	–

Parsed from the XBRL in 20/20 Biolabs's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AIDX.

Revenue growth16.7% · median -18.5%

Gross margin29.6% · median -10.2%

Operating margin-162.9% · median -695.7%

Net margin-182.8% · median -698.5%

Advertisement
300 × 250

See a number that looks wrong?